Previous Page
26
nanotimes
Companies Facts
L
eica Microsystems has acquired the microscopy and histopathology business of Labindia Instru-
ments Pvt. Ltd., a leading solutions and service provider in India.
http://www.leica-microsystems.com/products/ E L
ncap Drug Delivery and Lena Nanoceutics announced a collaboration agreement to deve-
lop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle en- gineering technology with Encap’s liquid filled hard capsule technology.
eonardo Biosystems, Inc., has received the second half of a $2.5 million award from the
Texas Emerging Technology Fund (TETF). The initi- al investment tranche was received in April 2010.
Leonardo’s lead technology consists of fully biode- gradable, porous silicon particles smaller than a red blood cell, which can be loaded with a diverse array of secondary nanoparticles such as liposomes, mi- celles, CNTs, dendrimers and metallic nanoparticles. In addition to bypassing many of the body’s natural defenses that lead to rapid clearance of nanoparti- cles administered alone, Leonardo’s particles can be designed to seek out tumor vasculature and can be tuned to create an intravascular depot. Leonardo is a portfolio company of Arrowhead Research Corpora- tion (NASDAQ: ARWR).
http://www.leonardobiosystems.com L iquidmetal® Technologies Inc. (OTCBB: LQMT) reported its financial results for the three months
ended September 30, 2011. The Company reported revenues of $2.9 million for the third quarter ended September 30, 2011. Furthermore, the Company closed out the quarter with an operating loss of $0.6 million excluding a one-time settlement char- ge of $1.1 million.
Mr. Tom Steipp, President and CEO, commented, “We continue to see progress against the goals that were established for this year with regard to commer- cializing the technology and implementing a part- nership model that will allow us to scale the business model with minimum capital investment. As part of our milestone tracking, the shipment of commercial parts prior to year end is our primary focus.”
agForce AG (FSE:MF6) announced the resignation of Prof. Dr. Walter Rust as chair-
man of the Supervisory Board as of October 25, 2011 due to health reasons. Effective October 28, 2011, Dr. Peter Heinrich stepped down from his position as MagForce CEO and is expected, at a future date, to return to his previous role as a mem- ber of the MagForce Supervisory Board. Until further appointments are confirmed, Dr. Andreas Jordan will represent the Management Board with the support of Prof. Dr. Hoda Tawfik, VP Clinical Development & Medical Affairs, and Solveig Salomon, VP Marketing & Sales.
11-10 :: October 2011